PortalPublikationenIntrinsic resistance to tyrosine kinase inhibitors is associ...

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma

Standard

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. / Busch, Jonas; Seidel, Christoph; Weikert, Steffen; Wolff, Ingmar; Kempkensteffen, Carsten; Weinkauf, Lisa; Hinz, Stefan; Magheli, Ahmed; Miller, Kurt; Grünwald, Viktor.

in: BMC CANCER, Jahrgang 11, 2011, S. 295.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Busch, J, Seidel, C, Weikert, S, Wolff, I, Kempkensteffen, C, Weinkauf, L, Hinz, S, Magheli, A, Miller, K & Grünwald, V 2011, 'Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma', BMC CANCER, Jg. 11, S. 295. https://doi.org/10.1186/1471-2407-11-295

APA

Busch, J., Seidel, C., Weikert, S., Wolff, I., Kempkensteffen, C., Weinkauf, L., Hinz, S., Magheli, A., Miller, K., & Grünwald, V. (2011). Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC CANCER, 11, 295. https://doi.org/10.1186/1471-2407-11-295

Vancouver

Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC CANCER. 2011;11:295. https://doi.org/10.1186/1471-2407-11-295

Bibtex

@article{693759792e794d459850bd89d8710b15,
title = "Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma",
abstract = "BACKGROUND: Data on sequential therapy in patients with metastatic renal cell carcinoma (mRCC) and intrinsic resistance to receptor tyrosine kinase inhibitor (rTKI) treatment remains vague.METHODS: We retrospectively studied treatment characteristics and outcome of mRCC patients refractory to first rTKI therapy.RESULTS: Thirty-five mRCC patients (male, 18; female, 11) with primary resistance to first rTKI therapy (sunitinib, n = 28; sorafenib, n = 7) and a median treatment interval of 2.4 months (1 - 4.6) were identified. In 22 patients, progressive disease (PD) was determined by a new metastatic lesion. Of these, 16 patients received subsequent therapy with 12 patients remaining refractory and 4 patients achieving disease stabilization. In 13 patients continuous growth of existing metastatic lesions determined PD. Of these, 9 received sequential therapy with 6 achieving disease stabilization. Altogether, 25 patients were treated sequentially (rTKI: n = 15; mTOR-inhibitor: n = 10) and achieved a median PFS of 3.2 months (range, 1-16.6). Fifteen patients failed to respond to either line of therapy. Disease control was not associated with type of subsequent therapy. Median OS was 14.9 months (CI: 5.5-24.4).CONCLUSION: Intrinsic resistance to rTKI is associated with a low chance of response to sequential therapy and a poor prognosis in mRCC patients.",
keywords = "Adult, Aged, Antineoplastic Agents, Benzenesulfonates, Carcinoma, Renal Cell, Drug Resistance, Neoplasm, Female, Humans, Indoles, Kaplan-Meier Estimate, Kidney Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Niacinamide, Phenylurea Compounds, Prognosis, Protein Kinase Inhibitors, Pyridines, Pyrroles, Retrospective Studies, Time Factors, Treatment Outcome",
author = "Jonas Busch and Christoph Seidel and Steffen Weikert and Ingmar Wolff and Carsten Kempkensteffen and Lisa Weinkauf and Stefan Hinz and Ahmed Magheli and Kurt Miller and Viktor Gr{\"u}nwald",
year = "2011",
doi = "10.1186/1471-2407-11-295",
language = "English",
volume = "11",
pages = "295",
journal = "BMC CANCER",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma

AU - Busch, Jonas

AU - Seidel, Christoph

AU - Weikert, Steffen

AU - Wolff, Ingmar

AU - Kempkensteffen, Carsten

AU - Weinkauf, Lisa

AU - Hinz, Stefan

AU - Magheli, Ahmed

AU - Miller, Kurt

AU - Grünwald, Viktor

PY - 2011

Y1 - 2011

N2 - BACKGROUND: Data on sequential therapy in patients with metastatic renal cell carcinoma (mRCC) and intrinsic resistance to receptor tyrosine kinase inhibitor (rTKI) treatment remains vague.METHODS: We retrospectively studied treatment characteristics and outcome of mRCC patients refractory to first rTKI therapy.RESULTS: Thirty-five mRCC patients (male, 18; female, 11) with primary resistance to first rTKI therapy (sunitinib, n = 28; sorafenib, n = 7) and a median treatment interval of 2.4 months (1 - 4.6) were identified. In 22 patients, progressive disease (PD) was determined by a new metastatic lesion. Of these, 16 patients received subsequent therapy with 12 patients remaining refractory and 4 patients achieving disease stabilization. In 13 patients continuous growth of existing metastatic lesions determined PD. Of these, 9 received sequential therapy with 6 achieving disease stabilization. Altogether, 25 patients were treated sequentially (rTKI: n = 15; mTOR-inhibitor: n = 10) and achieved a median PFS of 3.2 months (range, 1-16.6). Fifteen patients failed to respond to either line of therapy. Disease control was not associated with type of subsequent therapy. Median OS was 14.9 months (CI: 5.5-24.4).CONCLUSION: Intrinsic resistance to rTKI is associated with a low chance of response to sequential therapy and a poor prognosis in mRCC patients.

AB - BACKGROUND: Data on sequential therapy in patients with metastatic renal cell carcinoma (mRCC) and intrinsic resistance to receptor tyrosine kinase inhibitor (rTKI) treatment remains vague.METHODS: We retrospectively studied treatment characteristics and outcome of mRCC patients refractory to first rTKI therapy.RESULTS: Thirty-five mRCC patients (male, 18; female, 11) with primary resistance to first rTKI therapy (sunitinib, n = 28; sorafenib, n = 7) and a median treatment interval of 2.4 months (1 - 4.6) were identified. In 22 patients, progressive disease (PD) was determined by a new metastatic lesion. Of these, 16 patients received subsequent therapy with 12 patients remaining refractory and 4 patients achieving disease stabilization. In 13 patients continuous growth of existing metastatic lesions determined PD. Of these, 9 received sequential therapy with 6 achieving disease stabilization. Altogether, 25 patients were treated sequentially (rTKI: n = 15; mTOR-inhibitor: n = 10) and achieved a median PFS of 3.2 months (range, 1-16.6). Fifteen patients failed to respond to either line of therapy. Disease control was not associated with type of subsequent therapy. Median OS was 14.9 months (CI: 5.5-24.4).CONCLUSION: Intrinsic resistance to rTKI is associated with a low chance of response to sequential therapy and a poor prognosis in mRCC patients.

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Benzenesulfonates

KW - Carcinoma, Renal Cell

KW - Drug Resistance, Neoplasm

KW - Female

KW - Humans

KW - Indoles

KW - Kaplan-Meier Estimate

KW - Kidney Neoplasms

KW - Male

KW - Middle Aged

KW - Neoplasm Metastasis

KW - Niacinamide

KW - Phenylurea Compounds

KW - Prognosis

KW - Protein Kinase Inhibitors

KW - Pyridines

KW - Pyrroles

KW - Retrospective Studies

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1186/1471-2407-11-295

DO - 10.1186/1471-2407-11-295

M3 - SCORING: Journal article

C2 - 21756335

VL - 11

SP - 295

JO - BMC CANCER

JF - BMC CANCER

SN - 1471-2407

ER -